|
1.
|
Bettuzzi S, Brausi M, Rizzi F, Peracchia G
and Corti A: Chemoprevention of human prostate cancer by oral
administration of green tea catechins in volunteers with high-grade
prostate intraepithelial neoplasia: a preliminary report from a
one-year proof-of-principle study. Am Assoc Cancer Res.
66:1234–1240. 2006.PubMed/NCBI
|
|
2.
|
Hsieh TC and Wu JM: Targeting CWR22Rv1
prostate cancer cell proliferation and gene expression by
combinations of the phytochemicals EGCG, genistein, and quercetin.
Anticancer Res. 29:4025–4032. 2009.PubMed/NCBI
|
|
3.
|
Stuart Ec, Scandlyn MJ and Rosengren RJ:
Role of epigallocatechin gallate (EGCG) in the treatment of breast
and prostate cancer. Life Sci. 79:2329–2336. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Chen D and Dou QP: Tea polyphenols and
their roles in cancer prevention and chemotherapy. Int J Mol Sci.
9:1196–1206. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Philips BJ, Coyle CH, Morrisroe SN,
Chancellor MB and Yoshimura N: Induction of apoptosis in human
bladder cancer cells by green tea catechins. Biomed Res.
30:207–215. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Manoharan M, Fatima I, Saxena R, Chandra
V, Sankhwar PL and Dwivedi A: (-)-Epigallocatechin-3-gallate
induces apoptosis in human endometrial adenocarcinoma cells via ROS
generation and p38 MAP kinase activation. J Nutr Biochem. Sep
5–2012.(Epub ahead of print).
|
|
7.
|
Lim YC and Cha YY:
Epigallocatechin-3-gallate induces growth inhibition and apoptosis
of human anaplastic thyroid carcinoma cells through suppression of
EGFR/ERK pathway and cyclin B1/CDK1 complex. J Surg Oncol.
104:776–780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Onoda C, Kuribayashi K, Nirasawa S, Tsuji
N, Tanaka M, Kobayashi D and Watanabe N:
(-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer
cell lines by downregulating survivin expression. Int J Oncol.
38:1403–1408. 2011.PubMed/NCBI
|
|
9.
|
Shen Q, Tian F, Jiang P, Li Y, Zhang L, Lu
J and Li J: EGCG enhances TRAIL-mediated apoptosis in human
melanoma A375 cell line. J Huazhong Univ Sci Technolog Med Sci.
29:771–775. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Siddiqui IA, Malik A, Adhami VM, Asim M,
Hafeez BB, Sarfaraz S and Mukhtar H: Green tea polyphenol EGCG
sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated
apoptosis and synergistically inhibits biomarkers associated with
angiogenesis and metastasis. Oncogene. 27:2055–2063. 2007.
View Article : Google Scholar
|
|
11.
|
Lin HY, Hou SC, Chen SC, Kao MC, Yu CC,
Funayama S, Ho CT and Way TD: (-)-Epigallocatechin gallate induces
Fas/CD95-mediated apoptosis through inhibiting constitutive and
IL-6-induced JAK/STAT3 signaling in head and neck squamous cell
carcinoma cells. J Agric Food Chem. 60:2480–2489. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Singh M, Singh R, Bhui K, Tyagi S, Mahmood
Z and Shukla Y: Tea polyphenols induce apoptosis through
mitochondrial pathway and by inhibiting nuclear factor-kappaB and
Akt activation in human cervical cancer cells. Oncol Res.
19:245–257. 2011. View Article : Google Scholar
|
|
13.
|
Das A, Banik NL and Ray SK: Flavonoids
activated caspases for apoptosis in human glioblastoma T98G and
U87MG cells but not in human normal astrocytes. Cancer.
116:164–176. 2009.PubMed/NCBI
|
|
14.
|
Li GX, Chen YK, Hou Z, Xiao H, Jin H, Lu
G, Lee MJ, Liu B, Guan F, Yang Z, Yu A and Yang CS: Pro-oxidative
activities and dose-response relationship of
(-)-epigallocatechin-3-gal-late in the inhibition of lung cancer
cell growth: a comparative study in vivo and in vitro.
Carcinogenesis. 31:902–910. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Min NY, Kim JH, Choi JH, Liang W, Ko YJ,
Rhee S, Bang H, Ham SW, Park AJ and Lee KH: Selective death of
cancer cells by preferential induction of reactive oxygen species
in response to (-)-epigallocatechin-3-gallate. Biomed Biophys Res
Commun. 421:91–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Markus MA, Marques FZ and Morris BJ:
Resveratrol, by modulating RNA processing factor levels, can
influence the alternative splicing of pre-mRNAs. PLoS One.
6:e289262011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Anderson SL, Qiu J and Rubin BY: EGCG
corrects aberrant splicing of IKAP mRNA in cells from patients with
familial dysautonomia. Biochem Biophys Res Commun. 310:627–633.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Kim MH: Protein phosphatase 1 activation
and alternative splicing of Bcl-X and Mcl-1 by EGCG + ibuprofen. J
Cell Biochem. 104:1491–1499. 2008.PubMed/NCBI
|
|
19.
|
David CJ and Manley JL: Alternative
pre-mRNA splicing regulation in cancer: pathways and programs
unhinged. Genes Dev. 24:2343–2364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Miura K, Fujibuchi W and Unno M: Splice
variants in apoptotic pathway. Exp Oncol. 34:212–217.
2012.PubMed/NCBI
|
|
21.
|
Shultz JC, Goehe RW, Wijesinghe DS,
Murudkar C, Hawkins AJ, Shay JW, Minna JD and Chalfant CE:
Alternative splicing of caspase 9 is modulated by the
phosphoinositide 3-kinase/Akt pathway via phosphorylation of
SRp30a. Cancer Res. 70:9185–9196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Shultz JC, Goehe RW, Murudkar CS,
Wijesinghe DS, Mayton EK, Massiello A, Hawkins AJ, Mukerjee P,
Pinkerman RL, Park MA and Chalfant CE: SRSF1 regulates the
alternative splicing of caspase 9 via a novel intronic splicing
enhancer affecting the chemotherapeutic sensitivity of non-small
cell lung cancer cells. Mol Cancer Res. 9:889–900. 2011. View Article : Google Scholar
|
|
23.
|
Rasmussen R: Quantification on the
LightCycler. Rapid Cycle Real-Time PCR, Methods and Applications.
Meuer S, Wittwer C and Nakagawara K: Springer Press; Heidelberg:
pp. 2001
|
|
24.
|
Applied Biosystems: Guide to Performing
Relative Quantitation of Gene Expression Using Real-Time
Quantitative PCR, 2008.
|
|
25.
|
Havsteen BH: The biochemistry and medical
significance of the flavonoids. Pharmacol Ther. 96:67–202. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Crespy V, Morand C, Manach C, Besson C,
Demigne C and Remesy C: Part of quercetin absorbed in the small
intestine is conjugated and further secreted in the intestinal
lumen. Am J Physiol. 277:G120–G126. 1999.PubMed/NCBI
|
|
27.
|
Pforte H, Hempel J and Jacobasch G:
Distribution pattern of a flavonoid extract in the gastrointestinal
lumen and wall of rats. Nahrung. 43:205–208. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Albrecht DS, Clubbs EA, Ferruzzi M and
Bomser JA: Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate
cancer cell proliferation via MEK-independent ERK1/2 activation.
Chem Biol Interact. 171:89–95. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Yu HN, Shen SR and Yin JJ: Effects of
interactions of EGCG and cd(2+) on the growth of PC-3 cells and
their mechanisms. Food Chem Toxicol. 45:244–249. 2007.
|
|
30.
|
Caporali A, Davalli P, Astancolle S,
D’Arca D, Brausi M, Bettuzzi S and Corti A: The chemopreventive
action of catechins in the TRAMP mouse model of prostate
carcinogenesis is accompanied by clusterin over-expression.
Carcinogenesis. 25:2217–2224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Kurihara N, Kubota T, Hoshiya Y, Otani Y,
Ando N, Kumai K and Kitajima M: Pharmacokinetics of
cis-diamminedichloro-platinum (II) given as low-dose and high-dose
infusions. J Surg Oncol. 62:135–138. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Chan MM, Soprano KJ, Weinstein K and Fong
D: Epigallocatechin-3-gallate delivers hydrogen peroxide to induce
death of ovarian cancer cells and enhances their cisplatin
susceptibility. J Cell Physiol. 207:389–396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Yunos NM, Beale P, Yu JQ and Huq F:
Synergism from the combination of oxaliplatin with selected
phytochemicals in human ovarian cancer cell lines. Anticancer Res.
31:4283–4289. 2011.PubMed/NCBI
|
|
34.
|
Henning SM, Aronson W, Niu Y, Conde F, Lee
NH, Seeram NP, Lee RP, Lu J, Harris DM, Moro A, Hong J, Pak-Shan L,
Barnard RJ, Ziaee HG, Csathy G, Go VL, Wang H and Heber D: Tea
polyphenols and theaflavins are present in prostate tissue of
humans and mice after green and black tea consumption. J Nutr.
136:1839–1843. 2006.PubMed/NCBI
|
|
35.
|
Rohde J, Jacobsen C and Kromann-Andersen
H: Toxic hepatitis triggered by green tea. Ugeskr Laeger.
173:205–206. 2011.PubMed/NCBI
|
|
36.
|
Singh M, Bhatnagar P, Srivastava AK, Kumar
P, Shukla Y and Gupta KC: Enhancement of cancer chemosensitization
potential of cisplatin by tea polyphenols
poly(lactide-co-glycolide) nanoparticles. J Biomed Nanotechnol.
7:2022011. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Ge J, Tan BX, Chen Y, Yang L, Peng XC, Li
HZ, Lin HJ, Zhao Y, Wei M, Cheng K, Li LH, Dong H, Gao F, He JP, Wu
Y, Qiu M, Zhao YL, Su JM, Hou JM and Liu JY: Interaction of green
tea polyphenol epigallocatechin-3-gallate with sunitinib: potential
risk of diminished sunitinib bioavailability. J Mol Med (Berl).
89:595–602. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Amin EM, Oltean S, Hua J, Gammons MV,
Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES,
Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M,
Schumacher VA, Harper SJ, Hinton DR, Bates DO and Ladomery MR: WT1
mutants reveal SRPK1 to be a downstream angiogenesis target by
altering VEGF splicing. Cancer Cell. 20:768–780. 2011. View Article : Google Scholar : PubMed/NCBI
|
